MDXG241220C10000
- 0.20
- -0.10-33.33%
MiMedx Newsroom
Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and MiMedx Group (MDXG)
A Quick Look at Today's Ratings for MiMedx(MDXG.US), With a Forecast Between $12 to $16
Northland Securities Sticks to Their Buy Rating for MiMedx Group (MDXG)
A Quick Look at Today's Ratings for MiMedx(MDXG.US), With a Forecast Between $11 to $12
Cantor Fitzgerald Maintains MiMedx(MDXG.US) With Buy Rating, Maintains Target Price $11
Craig-Hallum Maintains MiMedx(MDXG.US) With Buy Rating
Craig-Hallum Maintains MiMedx(MDXG.US) With Buy Rating
Craig-Hallum Maintains MiMedx(MDXG.US) With Buy Rating
Craig-Hallum Maintains MiMedx(MDXG.US) With Buy Rating
Craig-Hallum Sticks to Its Buy Rating for MiMedx Group (MDXG)
Northland Securities Maintains MiMedx(MDXG.US) With Buy Rating, Maintains Target Price $12
MiMedx Group Analyst Ratings
Lake Street Maintains MiMedx(MDXG.US) With Buy Rating, Maintains Target Price $12
Northland Securities Maintains MiMedx(MDXG.US) With Buy Rating, Maintains Target Price $12
Analysts Offer Insights on Healthcare Companies: Option Care Health (OPCH), Qiagen (QGEN) and MiMedx Group (MDXG)
Lake Street Sticks to Its Buy Rating for MiMedx Group (MDXG)
Cantor Fitzgerald Maintains MiMedx(MDXG.US) With Buy Rating, Maintains Target Price $11
MiMedx Group (MDXG) Gets a Buy From Cantor Fitzgerald
Craig-Hallum Maintains MiMedx(MDXG.US) With Buy Rating
Craig-Hallum Maintains MiMedx(MDXG.US) With Buy Rating